On August 18, 2025, the 2025 Innovation Summit of Shenzhen Chipscreen Biosciences Co., Ltd. (Stock Code: 688321.SH) was successfully held in Shanghai. The summit provided an in-depth interpretation of the application of the company's AI-assisted design + chemogenomics integrated technology platform in new drug R&D, comprehensively showcased the company's extensive clinical pipeline both domestically and internationally, and detailed the next generation of global First-in-Class early-stage R&D pipelines developed based on the comprehensive AI platform. Over a hundred industry experts, including leading clinical investigators, institutional investors, and media representatives from China, participated in the summit to jointly explore new pathways for biopharmaceutical innovation.

Dr. Lu Xianping, Founder, Chairman, and General Manager of Chipscreen Biosciences, stated that the company focuses on developing original new molecular entities that target major diseases, possess global patent protection, and offer unique clinical benefits.. The company strategically focuses on oncology and metabolism based on its marketed products, continuously addresses significant unmet clinical needs in areas such as neurodegenerative and autoimmune diseases, and explores the application of new technological modalities in drug development. Currently, the company has successfully commercialized two global First-in-Class drugs, Chidamide and Chiglitazar Sodium, with multiple indications marketed in Mainland China, Taiwan, China, and Japan.

AI-Assisted Design + Chemogenomics Integrated Technology Platform Empowers R&D

As a pioneer in China's AI for R&D field, Chipscreen Biosciences has been at the forefront of global biotechnology since its inception. Utilizing microarray biochip technology, the company delves into the impact of chemical structures on human gene expression, acquires massive datasets on drug action, and employs efficient algorithms to identify compounds with therapeutic potential. Dr. Pan Desi, Chief Scientific Officer of Chipscreen Biosciences, presented a detailed overview of the latest advancements in the AI + chemogenomics core technology platform. The upgraded core technology platform offers enhanced support in areas such as molecular design and structural optimization, drug-likeness assessment, clinical development strategy, and comprehensive risk control. This contributes to improving development success rates, accelerating the R&D process, and reducing costs.

Research Strategy for Anti-Tumor Therapeutics with Multi-Target, Multi-Mechanism Synergy

Despite advancements in new technologies such as surgery, radiotherapy/chemotherapy, targeted therapy, and immunotherapy ushering tumor treatment into a new era of multi-mechanism synergy, there remains significant room for improvement in patients' long-term survival benefits and quality of life. Dr. Pan Desi noted that Chipscreen Biosciences has strategically developed treatment regimens employing multiple drug modalities to address the complex characteristics of tumors. In the field of immunotherapy, the combination of HDAC inhibitors and immunotherapy (HDACi+IO) has shown excellent potential in clinical trials worldwide, offering a promising solution for immune-refractory tumors. Beyond the two ongoing pivotal clinical studies for Chidamide worldwide, Chipscreen Biosciences has also advanced its pipeline with next-generation products such as the immune-activating antibody-drug conjugate NW001 and the small-molecule PD-L1 inhibitor CS23546. Additionally, the company has strategically invested in areas including tumor microenvironment modulation, synthetic lethality, and targeted chemotherapy, with some molecules already progressing to the global clinical development stage.

Chiauranib-Based First-Line Combination Regimen Challenges the King of Cancers

According to the latest data from the World Health Organization's GLOBOCAN project, pancreatic cancer causes nearly 470,000 annual deaths worldwide, ranking 6th among all cancer-related fatalities. Currently, chemotherapy remains the primary treatment for pancreatic ductal adenocarcinoma. The first-line standard of care based on nab-paclitaxel has a response rate of only 23%, with median progression-free survival (mPFS) and median overall survival (mOS) of only about half a year and less than one year, respectively. Chiauranib is a First-in-Class molecule developed by Chipscreen Biosciences that selectively inhibits protein kinase targets involved in tumorigenesis and progression, such as Aurora B, CSF1R, and VEGFR/PDGFR/c-Kit. Based on the preliminary efficacy signals observed in US patients with  pancreatic cancer who were treated with Chiauranib, Chipscreen Biosciences has initiated a Phase II clinical study in China evaluating Chiauranib combined with the AG regimen as first-line treatment for advanced pancreatic ductal adenocarcinoma. An investigator from Fudan University Shanghai Cancer Center reported that the combination of Chiauranib and the AG combination regimen demonstrated favorable anti-tumor activity and a manageable safety profile, with preliminary data supporting further investigation of Chiauranib in pancreatic cancer.

Comprehensive Metabolic Disease Management: From Gluco-Hepatic Co-Management to Next-Generation Weight-Loss Drugs

Metabolic diseases encompass a wide range of conditions with numerous comorbidities. Chiglitazar Sodium (Bilessglu) is the world's first PPAR pan-agonist, demonstrating excellent performance in clinical studies for diabetes and metabolic dysfunction-associated steatohepatitis (MASH), offering the unique advantage of gluco-hepatic co-management. Chipscreen Biosciences is committed to establishing Chiglitazar Sodium as a cornerstone therapy for metabolic diseases. Obesity has become a global health issue. In recent years, incretin-based drugs, represented by GLP-1R agonists, have revolutionized the interventional paradigm in this field. However, existing therapies still leave significant unmet needs, including muscle loss, weight regain, gastrointestinal side effects, potential central nervous system adverse reactions, and challenges related to administration convenience. Dr. Shan Song, Head of the Early R&D Center at Chipscreen Biosciences, outlined the company's First-in-Class small-molecule drug pipeline in the high-quality weight management arena. Among them, CDCS28, a non-incretin small-molecule agent that does not affect appetite, showed promising potential in preclinical studies for monotherapy weight reduction, weight maintenance, and muscle preservation, while avoiding central nervous system-related risks..

Early-Stage Research Progresses Across Alzheimer's Disease, Autoimmune Disorders, and Fibrotic Diseases

Alzheimer's disease (AD) still lacks effective therapeutic drugs. ApoE4 (Apolipoprotein E4) is the strongest genetic risk factor for Alzheimer's disease, and some researchers also consider it a causative gene. 36.7% of patients with Alzheimer's disease carry at least one ApoE4 gene.

CDCS04 is the world's first small-molecule drug development program targeting the ApoE4. Based on the AI-assisted design + chemogenomics integrated technology platform, Chipscreen Biosciences has discovered a series of active ApoE4 candidate molecules. These candidate molecules exhibit high blood-brain barrier permeability, favorable in vivo safety, and have shown protective effects on neurite outgrowth in ApoE4-expressing cells in preclinical studies. They also significantly reduce phosphorylated Tau protein levels in the cortex and hippocampus of ApoE4 transgenic mouse models..

TYK2 is a potential therapeutic target for autoimmune diseases such as psoriasis. CS32582 is a novel, highly selective small-molecule allosteric inhibitor of  TYK2 independently discovered by Chipscreen Biosciences. In Phase I clinical studies, CS32582 demonstrated excellent in vivo pharmacodynamic characteristics. Furthermore, its relatively moderate half-life provides a wider therapeutic window, offering potential for expanding its indications beyond psoriasis. Fibrotic diseases, including pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and idiopathic pulmonary fibrosis (IPF), lack safe and effective treatments, and traditional standard therapies face pressure from patent expirations. CS1011, independently discovered by Chipscreen Biosciences using its integrated AI-assisted design and chemogenomics platform, potently and selectively inhibits PDGFR and CSF-1R. It blocks the interaction between fibroblasts and inflammatory macrophages, thereby ameliorating fibrotic diseases by targeting key pathological drivers. In multiple animal models of fibrosis, CS1011 has demonstrated superior efficacy compared to existing standard-of-care agents.

Focused on Source Innovation and Developing Globally Leading Therapies. As a pioneer in China's original new drug development, Chipscreen Biosciences will continue to discover new molecular entities addressing major diseases through its integrated AI-assisted design and chemogenomics technology platform, safeguarding and advancing global human health.